Based in the Boston biotech and medtech hub, Elucid Bioimaging is focused on improving the accuracy, experience, & cost-effectiveness of cardiovascular diagnostic imaging by leveraging machine learning. Elucid's main product, vascuCAP, is the first-ever, FDA-cleared, histologically-validated software for evaluating plaque vulnerability from a single CTA to inform risk of event (heart attack or stroke) & treatment selection. Additionally, Elucid works with pharmaceutical companies, providers, and research organizations to provide quantitative image analysis services.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.